| Detected | Trial | Change |
|---|---|---|
| 2026-08-14 | NCT03858322 'ADVANCE' (A Pilot Trial) |
date change Completion pushed: 2026-06-30 -> 2026-12-30 |
| 2026-08-13 | NCT02657551 A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid… |
Trial completed |
| 2026-08-13 | NCT02657551 A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid… |
Primary endpoint(s) modified |
| 2026-08-13 | NCT02657551 A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid… |
Enrollment increased: 8 -> 17 participants |
| 2026-08-13 | NCT02657551 A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid… |
date change Primary completion moved earlier: 2025-12 -> 2023-08-07 |
| 2026-08-13 | NCT02657551 A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid… |
date change Completion moved earlier: 2025-12 -> 2023-08-07 |
| 2026-08-12 | NCT07426484 Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy |
Recruitment opened |
| 2026-08-12 | NCT03392246 A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-08-12 | NCT03392246 A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve… |
date change Completion pushed: 2026-12-30 -> 2027-12-30 |
| 2026-08-11 | NCT07482384 Supporting Health Including Endocrine Treatment for Long Duration |
Recruitment opened |
| 2026-08-11 | NCT06026111 Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With… |
date change Primary completion pushed: 2026-12-31 -> 2027-12-31 |
| 2026-08-11 | NCT06026111 Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With… |
date change Completion pushed: 2027-12-31 -> 2028-12-31 |
| 2026-08-06 | NCT07412041 Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study |
Recruitment opened |
| 2026-08-06 | NCT07412041 Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study |
date change Primary completion moved earlier: 2027-09-30 -> 2027-03-30 |
| 2026-08-06 | NCT07412041 Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study |
date change Completion moved earlier: 2028-09-30 -> 2028-03-30 |
| 2026-08-05 | NCT06736548 Sleep Treatment Education Program for Cancer Survivors: STEP-Together |
overall status: Recruiting → Enrolling by Invitation |
| 2026-08-05 | NCT06736548 Sleep Treatment Education Program for Cancer Survivors: STEP-Together |
date change Primary completion pushed: 2026-10-31 -> 2027-06-30 |
| 2026-08-05 | NCT06736548 Sleep Treatment Education Program for Cancer Survivors: STEP-Together |
date change Completion pushed: 2026-12-31 -> 2027-10-31 |
| 2026-08-05 | NCT05080166 UPLYFT For Lymphoma Survivors |
Trial completed |
| 2026-08-05 | NCT05080166 UPLYFT For Lymphoma Survivors |
date change Primary completion pushed: 2026-05-31 -> 2026-07-17 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-07-30 | NCT07735442 BRIDGE-SIC Efficacy Trial | Not Yet Recruiting | |
| 2026-07-30 | NCT07735624 RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer | Phase 2 | Not Yet Recruiting |
| 2026-07-28 | NCT07732140 Listen Aphasia Pilot Study | Not Yet Recruiting | |
| 2026-07-27 | NCT07729150 Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes | Not Yet Recruiting | |
| 2026-07-20 | NCT07714551 Zanzalintinib in Unresectable and Progressive MPGGs | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07426484 | Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy | Cutaneous Squamous Cell Carcinoma | Recruiting |
| Phase 3 | |||
| NCT07624513 | Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction… | Multiple Myeloma | Not Yet Recruiting |
| NCT03020030 | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | Acute Lymphoblastic Leukemia, Pediatric | Active, Not Recruiting |
| Phase 2 | |||
| NCT06677190 | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin | Ovarian Cancer | Recruiting |
| NCT05168930 | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | Chronic Lymphocytic Leukemia (CLL) | Recruiting |
| NCT06366347 | ALPINE: Maintenance Letrozole/Abemaciclib | Endometrial Cancer | Recruiting |
| NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | Renal Cell Carcinoma | Recruiting |
| NCT07465276 | Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC | Head and Neck Squamous Cell Carcinoma (HNSCC) | Recruiting |
| NCT04620187 | Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | Salivary Gland Cancer | Recruiting |
| NCT07123649 | Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors… | Breast Cancer | Recruiting |
| NCT03310879 | Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations… | Cancer | Recruiting |
| NCT04468061 | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Breast Cancer | Recruiting |
| NCT04434040 | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | Breast Cancer | Recruiting |
| NCT07434843 | PH 2 Pemigatinib in SDH-deficient GIST | SDH Gene Mutation | Recruiting |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | Uterine Sarcoma | Recruiting |
| NCT05922761 | BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) | Bronchiolitis Obliterans Syndrome | Recruiting |
| NCT04986579 | Scalp Cooling in MBC | Metastatic Breast Cancer | Recruiting |
| NCT03675893 | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer | Endometrial Cancer | Recruiting |
| NCT05726370 | Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC | Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT04893109 | ATEMPT 2.0: Adjuvant T-DM1 vs TH | Breast Cancer | Recruiting |
| NCT05765500 | RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | Prostate Cancer | Recruiting |
| NCT06239220 | PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | Head and Neck Cancer | Recruiting |
| NCT06439693 | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic… | Breast Cancer Female | Recruiting |
| NCT03341936 | Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab… | Squamous Cell Carcinoma of the Head and Neck | Active, Not Recruiting |
| NCT04482244 | RCT of CBD for Anxiety in Advanced Breast Cancer | Advanced Breast Cancer | Active, Not Recruiting |